Objective: This study explores the efficacy of remimazolam combined with sufentanil in managing anesthesia for patients undergoing thoracoscopic surgery. Methods: A simple random sampling method selected 178 patients from our hospital between May 2021 and May 2022. Patients were randomly divided into two groups: the control group (CG) received sufentanil alone, whereas the observation group (OG) received a combination of remimazolam and sufentanil. Pain mediators, inflammatory factors, and plasma stress response indicators were measured and compared preoperatively and at 1, 3, 12, 24, and 48 h postoperation. The occurrence of adverse reactions (ARs) postoperation was also monitored. Results: Out of 178 patients, two were excluded – one from the CG who underwent open surgery and one from the OG who voluntarily withdrew – resulting in 176 patients with a data recovery rate of 98.88%. Repeated measurement analysis of variance indicated significant differences in levels of prostaglandin E2, high mobility group proteins, interleukin-6/10/17, tumor necrosis factor α, adrenaline, norepinephrine, cortisol, and fasting blood glucose between groups and over time ( P 0.05). Conclusion: The combination of remimazolam and sufentanil effectively inhibits the release of pain mediators and inflammatory factors in patients undergoing thoracoscopic surgery, alleviates postoperative stress responses, and demonstrates acceptable safety.
Jiang et al. (Thu,) studied this question.